List view / Grid view
A team of researchers have developed the first vascularised organoid model of human pancreatic islets, which could lead to further development of advanced cell therapies for diabetes.
Researchers in Norway have identified a promising oral drug combination that may stop the replication of enteroviruses, a group of viruses responsible for illnesses ranging from the common cold to type 1 diabetes.
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
The partial remission phase of type 1 diabetes, in which residual β-cells recover insulin production, offers new hope for therapeutic action.
Study led by UW Medicine reveals concerns about insulin pump therapy for type 1 diabetes patients. Long-term pump usage can lead to fibrotic, irritated infusion sites, making insulin delivery less effective
Researchers have discovered a new pathway to the regeneration of insulin in pancreatic stem cells, findings that could move towards new therapies for type 1 and type 2 diabetes.
The new study highlights 11 genes which could be considered as potential candidates for novel therapeutics for type 1 diabetes.
Scientists have developed a novel type 1 diabetes treatment that involves transplanting pancreas cells that produce insulin.
In a new study, researchers from Osaka University have highlighted that mesenchymal stem cells could repress type 1 diabetes caused by cancer drugs.
A new study has identified harmful cellular pathways that prevent insulin production, presenting a drug target for diabetes.
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
